RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Intercept Pharmaceuticals Stock

Intercept Pharmaceuticals Revenue 2024

Intercept Pharmaceuticals Revenue

368.48 M USD

Ticker

ICPT

ISIN

US45845P1084

WKN

A1J5U0

In 2024, Intercept Pharmaceuticals's sales reached 368.48 M USD, a 9.09% difference from the 337.77 M USD sales recorded in the previous year.

The Intercept Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2030e435.765,35
2029e505.2456,35
2028e344.0482,76
2027e354.6480,29
2026e370.6376,82
2025e368.7377,22
2024e368.4877,27
2023e337.7784,30
2022285.7199,66
2021260.7599,54
2020312.798,31
201925298,33
2018179.898,61
201713198,93
2016251138,90
20152.810168,79
20141.716748,59
20131.617795,38
20122.411863,58
20111.815818,11
2010--

Intercept Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Intercept Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Intercept Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Intercept Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Intercept Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Intercept Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Intercept Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Intercept Pharmaceuticals’s growth potential.

Intercept Pharmaceuticals Revenue, EBIT and net profit per share

DateIntercept Pharmaceuticals RevenueIntercept Pharmaceuticals EBITIntercept Pharmaceuticals Net Income
2030e435.7 M undefined42.36 M undefined9.81 M undefined
2029e505.24 M undefined96.34 M undefined50.96 M undefined
2028e344.04 M undefined97.12 M undefined65.39 M undefined
2027e354.64 M undefined101.85 M undefined68.83 M undefined
2026e370.63 M undefined116.5 M undefined71.08 M undefined
2025e368.73 M undefined107.98 M undefined73.88 M undefined
2024e368.48 M undefined102.71 M undefined87.25 M undefined
2023e337.77 M undefined-45.95 M undefined-55.73 M undefined
2022285.71 M undefined-68.22 M undefined221.82 M undefined
2021260.75 M undefined-100.69 M undefined-91.43 M undefined
2020312.7 M undefined-218.6 M undefined-274.9 M undefined
2019252 M undefined-312.4 M undefined-344.7 M undefined
2018179.8 M undefined-285.5 M undefined-309.2 M undefined
2017131 M undefined-335.6 M undefined-360.4 M undefined
201625 M undefined-402.5 M undefined-412.8 M undefined
20152.8 M undefined-229.2 M undefined-226.4 M undefined
20141.7 M undefined-113.2 M undefined-283.2 M undefined
20131.6 M undefined-39.5 M undefined-67.8 M undefined
20122.4 M undefined-18.9 M undefined-46.3 M undefined
20111.8 M undefined-13.8 M undefined-15.7 M undefined
20100 undefined-16.4 M undefined-18 M undefined

Intercept Pharmaceuticals stock margins

The Intercept Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Intercept Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Intercept Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Intercept Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Intercept Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Intercept Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Intercept Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Intercept Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Intercept Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Intercept Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Intercept Pharmaceuticals Margin History

Intercept Pharmaceuticals Gross marginIntercept Pharmaceuticals Profit marginIntercept Pharmaceuticals EBIT marginIntercept Pharmaceuticals Profit margin
2030e99.66 %9.72 %2.25 %
2029e99.66 %19.07 %10.09 %
2028e99.66 %28.23 %19.01 %
2027e99.66 %28.72 %19.41 %
2026e99.66 %31.43 %19.18 %
2025e99.66 %29.28 %20.04 %
2024e99.66 %27.87 %23.68 %
2023e99.66 %-13.6 %-16.5 %
202299.66 %-23.88 %77.64 %
202199.54 %-38.62 %-35.06 %
202098.31 %-69.91 %-87.91 %
201998.33 %-123.97 %-136.79 %
201898.61 %-158.79 %-171.97 %
201798.93 %-256.18 %-275.11 %
201699.66 %-1,610 %-1,651.2 %
201599.66 %-8,185.71 %-8,085.71 %
201499.66 %-6,658.82 %-16,658.82 %
201399.66 %-2,468.75 %-4,237.5 %
201299.66 %-787.5 %-1,929.17 %
201199.66 %-766.67 %-872.22 %
201099.66 %0 %0 %

Intercept Pharmaceuticals Aktienanalyse

What does Intercept Pharmaceuticals do?

Intercept Pharmaceuticals Inc is a biotechnology company based in New York City that focuses on the discovery and development of therapeutics for the treatment of chronic liver diseases. The company was founded in 2002 and has since brought a variety of innovative drugs to the market. The business model of Intercept Pharmaceuticals Inc is based on the invention, development, and marketing of drugs that specifically target certain disease conditions. They primarily focus on the development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These two diseases are prevalent worldwide and pose significant health problems in many Western societies. Intercept Pharmaceuticals Inc has already achieved significant success in the treatment of NAFLD and NASH. The various divisions of Intercept Pharmaceuticals Inc can be divided into research, development of new products, sale of existing drugs, and collaboration with partners and other companies. In research, the company strives to develop the most effective and safe medications, utilizing state-of-the-art technologies and research methods. The main products of Intercept Pharmaceuticals Inc are Ocaliva and obeticholic acid. Ocaliva is a medication used to treat primary biliary cholangitis, a disease that causes inadequate movement of bile through the liver and its accumulation in the body. Ocaliva helps improve bile production and alleviate the symptoms of this disease. Obeticholic acid is a new approach to the treatment of NASH and is currently being tested in clinical trials. Intercept Pharmaceuticals Inc works closely with other companies and organizations to ensure the most effective therapy for patients worldwide. Interaction with industry colleagues, scientific institutions, and experts in the field of medical research allows for faster development of new products that benefit patients. Overall, Intercept Pharmaceuticals Inc has achieved an impressive track record in recent years. The company has established a strong position in the field of liver diseases by advancing research and development in innovative ways. The focus on NAFLD and NASH allows Intercept Pharmaceuticals Inc to play a leading role in this market segment and provide patients with effective medications for their conditions. In summary, Intercept Pharmaceuticals Inc is a company dedicated to the development and marketing of products for the treatment of liver diseases. Through the use of innovative technologies and close collaboration with other companies and organizations, Intercept Pharmaceuticals Inc has already achieved significant success in the development of new medications. The company has established a strong position in this market segment and aims to develop further innovative products to combat liver diseases in the future. Intercept Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Intercept Pharmaceuticals's Sales Figures

The sales figures of Intercept Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Intercept Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Intercept Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Intercept Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Intercept Pharmaceuticals stock

How much revenue did Intercept Pharmaceuticals generate this year?

Intercept Pharmaceuticals has achieved a revenue of 368.48 M USD this year.

How much was the turnover of the company Intercept Pharmaceuticals compared to the previous year?

The revenue of Intercept Pharmaceuticals has increased by 9.09% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Intercept Pharmaceuticals?

The revenue of Intercept Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Intercept Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Intercept Pharmaceuticals so important for investors?

The revenue of Intercept Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Intercept Pharmaceuticals pay?

Over the past 12 months, Intercept Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intercept Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Intercept Pharmaceuticals?

The current dividend yield of Intercept Pharmaceuticals is .

When does Intercept Pharmaceuticals pay dividends?

Intercept Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intercept Pharmaceuticals?

Intercept Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Intercept Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intercept Pharmaceuticals located?

Intercept Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intercept Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intercept Pharmaceuticals from 10/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/9/2024.

When did Intercept Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/9/2024.

What was the dividend of Intercept Pharmaceuticals in the year 2023?

In the year 2023, Intercept Pharmaceuticals distributed 0 USD as dividends.

In which currency does Intercept Pharmaceuticals pay out the dividend?

The dividends of Intercept Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Intercept Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Intercept Pharmaceuticals

Our stock analysis for Intercept Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intercept Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.